OBJECTIVE： To investigate the characteristics and regularity of adverse drug reaction （ADR） in cancer hospital in order to provide reference for clinical rational use of drugs.  METHODS： A total of 157 cases of ADR reported by our hospital to the State ADR Monitoring Center from 2013 to 2014 were analyzed retrospective. RESULTS： Among 157 cases of ADR reports， there were no obvious difference between men and women， and the cases mainly occurred from the age of 61 to 70 （49 cases， 31.21％）. Ⅳ injection was the most probably way to cause the ADR （148 cases， 94.27％）. The main ADR-inducing drugs was antineoplastic drugs， among which the plant-derived antineoplastic drugs caused the large number of ADR reports （29 cases， 40.28％）. The hematological system was the main system involved in ADR reports （92 cases， 35.94％）. Top 5 ADR-inducing drugs were Paclitaxel injection （16 cases， 10.19％）， Nedaplatin for injection （16 cases， 10.19％）， Ribonucleic acid Ⅱ for injection （13 cases， 8.28％）， Docetaxel for injection （7 cases， 4.46％） and Compound amino acids （15） and dipeptides （2） injection （6 cases， 3.82％）. There were 38 cases of new ADRs （24.20％）， 59 cases of serious ADRs （37.58％） and 60 cases of general ADRs （38.22％）. 50 cases of the ADRs were cured， 102 cases were improved and only 5 cases were not improved. The most majority of serious ADRs were about the myelosuppression （50 cases， 84.74％）， while the serious ADRs were firstly induced by Paclitaxel injection （14 cases， 23.73％）. CONCLUSIONS： It is important to strengthen ADR monitoring and reporting of antineoplastic drugs and adjuvant therapeutic drugs， in order to most likely prevent and reduce the occurrence of ADR， guarantee the safe use of drugs.